The National Research Council is embarking on a re-alignment of its core strengths by reaching out to academia and other players in the federal innovation system (see lead article). NEOMED is making major strides retaining critical pharmaceutical talent in the Montreal region and its actively considering a third site for its potent combination of research expertise and business collaboration
Montreal’s NEOMED Institute needs more space to accommodate growing demand for its facilities and services. Discussions are underway with an unnamed third party equity investor to finance the expansion of its Laval facility with a decision expected within weeks. NEOMED’s growth proves it is possible to come up with a business model that can retain top talent in a region when big pharma employers decide to move out.
Dr Max Fehlmann has been appointed president and CEO of the Canadian Cancer Society, effective January 16, replacing Andy Chabot after an eight-year term. Fehlmann stepped down as the founding president and CEO of the NEOMED Institute and NEOMED-LABS, its affiliate contract research organization at the end of 2016. Prior to founding NEOMED in 2012,…